BS_FEV5A0HN
high-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- high-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- high-grade glioma
- overall_survival_months
- 86.2023653088042
- age_years
- 3.849
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.472
- G2M_CHECKPOINT+0.407
- MITOTIC_SPINDLE+0.243
- MYC_TARGETS_V1+0.230
- SPERMATOGENESIS+0.216
- PANCREAS_BETA_CELLS+0.206
- WNT_BETA_CATENIN_SIGNALING+0.074
- HEDGEHOG_SIGNALING+0.073
- DNA_REPAIR+0.034
- KRAS_SIGNALING_DN+0.026
Top 10 suppressed
- IL6_JAK_STAT3_SIGNALING-0.520
- INTERFERON_ALPHA_RESPONSE-0.511
- TNFA_SIGNALING_VIA_NFKB-0.489
- ALLOGRAFT_REJECTION-0.482
- ANGIOGENESIS-0.482
- INTERFERON_GAMMA_RESPONSE-0.476
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.475
- INFLAMMATORY_RESPONSE-0.469
- APOPTOSIS-0.442
- IL2_STAT5_SIGNALING-0.415
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
2 twins match this tumor's tissue · 8 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-03886 | — | cohortMD1 | 0.945 |
| 2 | BS_A14Z8BBK | medulloblastoma | — | 0.937 |
| 3 | BS_NKRYMHEP | medulloblastoma | — | 0.936 |
| 4 | BS_4PH1MBGR | medulloblastoma | — | 0.936 |
| 5 | TCGA-52-7809-01A-21R-2125-07 | — | cohortMD1 | 0.932 |
| 6 | BS_W9AT0MR7 | medulloblastoma | — | 0.932 |
| 7 | BS_QEYPFYHD | medulloblastoma | — | 0.931 |
| 8 | BS_FBJ5Q54N | Embryonal tumors | — | 0.929 |
| 9 | BS_1TWCV047 | Embryonal tumors | — | 0.929 |
| 10 | BS_QWNBZ9RJ | Embryonal tumors | — | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.472 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.407 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.243 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.216 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.206 | Cobimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.074 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.073 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.034 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.026 | Remibrutinib | — uncovered |